Intervention not reported
Interferon vs.control · Participants with recurrent liver graft infection with hepatitis C virus.
It is very uncertain whether the intervention changes interferon vs.control (very low certainty).
1 finding from 1 review
Intervention not reported
Interferon plus ribavirin vs.control · Participants with recurrent liver graft infection with hepatitis C virus.
It is very uncertain whether the intervention changes interferon plus ribavirin vs.control (very low certainty).
1 finding from 1 review
Intervention not reported
Ribavirin vs.interferon · Participants with recurrent liver graft infection with hepatitis C virus.
1 finding from 1 review
Intervention not reported
Retransplantation after start of therapy ‐ interferon vs.control · Participants with recurrent liver graft infection with hepatitis C virus.
It is very uncertain whether the intervention changes retransplantation after start of therapy ‐ interferon vs.control (very low certainty).
1 finding from 1 review
Relapse · patients with relapsing‐remitting multiple sclerosis
Alemtuzumab 12 mg probably leads to lower number of participants experiencing at least one relapse compared with interferon beta 1a (moderate certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · patients with relapsing‐remitting multiple sclerosis
Alemtuzumab 24 mg showed no clear difference in number of participants with at least one adverse event compared with interferon beta 1a (low certainty).
1 finding from 1 review
Number of participants with serious adverse events · patients with relapsing‐remitting multiple sclerosis
Alemtuzumab 24 mg showed no clear difference in number of participants with serious adverse events compared with interferon beta 1a (moderate certainty).
1 finding from 1 review
Mean Expanded Disability Status Scale score change from baseline · patients with relapsing‐remitting multiple sclerosis
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · patients with relapsing‐remitting multiple sclerosis
It is very uncertain whether alemtuzumab 24 mg changes number of participants experiencing treatment discontinuation caused… compared with interferon beta 1a (very low certainty).
1 finding from 1 review
Number of participants whose disability worsened · patients with relapsing‐remitting multiple sclerosis
Alemtuzumab 12 mg may leads to lower number of participants whose disability worsened compared with interferon beta 1a (low certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · patients with relapsing‐remitting multiple sclerosis
Alemtuzumab 12 mg showed no clear difference in number of participants with at least one adverse event compared with interferon beta 1a (low certainty).
1 finding from 1 review
Number of participants with serious adverse events · patients with relapsing‐remitting multiple sclerosis
Alemtuzumab 12 mg showed no clear difference in number of participants with serious adverse events compared with interferon beta 1a (moderate certainty).
1 finding from 1 review
Mean Expanded Disability Status Scale score change from baseline · patients with relapsing‐remitting multiple sclerosis
1 finding from 1 review
Number of participants with new T2‐hyperintense lesions on magnetic resonance imaging · patients with relapsing‐remitting multiple sclerosis
Alemtuzumab 12 mg may leads to lower number of participants with new T2‐hyperintense lesions on magnetic… compared with interferon beta 1a (low certainty).
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · patients with relapsing‐remitting multiple sclerosis
Alemtuzumab 12 mg may leads to lower number of participants experiencing treatment discontinuation caused… compared with interferon beta 1a (low certainty).
1 finding from 1 review
Relapse · patients with relapsing‐remitting multiple sclerosis
Alemtuzumab 24 mg may leads to lower number of participants experiencing at least one relapse compared with interferon beta 1a (low certainty).
1 finding from 1 review
Number of participants whose disability worsened · patients with relapsing‐remitting multiple sclerosis
Alemtuzumab 24 mg may leads to lower number of participants whose disability worsened compared with interferon beta 1a (low certainty).
1 finding from 1 review
Intervention not reported
Intervention (no. of studies/participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Mitoxantrone (Direct evidence; 1 RCT; 51 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
The intervention may leads to lower mitoxantrone (Direct evidence; 1 RCT; 51 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Natalizumab (Direct evidence; 1 RCT; 942 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
The intervention leads to lower natalizumab (Direct evidence; 1 RCT; 942 participants) (high certainty).
1 finding from 1 review